Zhitong Finance App News, Kangzhe Pharmaceutical (00867.HK) announced that on September 11, 2026, the innovative drug CMS-D001 tablets obtained a drug clinical trial approval notice issued by China's National Drug Administration (NMPA), and received a drug clinical trial approval notice on September 14, 2026. NMPA agreed with the Group to conduct clinical trials to evaluate the efficacy and safety of CMS-D001 in the treatment of systemic lupus erythematosus.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Kangzhe Pharmaceutical (00867.HK) announced that on September 11, 2026, the innovative drug CMS-D001 tablets obtained a drug clinical trial approval notice issued by China's National Drug Administration (NMPA), and received a drug clinical trial approval notice on September 14, 2026. NMPA agreed with the Group to conduct clinical trials to evaluate the efficacy and safety of CMS-D001 in the treatment of systemic lupus erythematosus.